At the end of December 2022, “the President signed into law the Consolidated appropriations Act, 2023 (Pub. L. 117-328), which included the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), which among other things provided the FDA with mandatory recall authority for cosmetic products”. Almost three and a half years later, the FDA has finally […]
While cosmetics have been included in the Federal Food, Drug, and Cosmetics (FD&C) Act since its passage in 1938, the Agency saw limited expansion of its authority between 1938 and 2022. However, with the passage of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) on December 29, 2022, that all changed. MoCRA gave new authority […]
At Lachman Consultant Services, we pride ourselves on being a preferred partner for quality, compliance, and regulatory consulting services for the life-sciences sector. However, we provide services to every sector regulated by the FDA except food and tobacco, and there are a lot of changes coming down the pike in the regulation of cosmetic products […]
The FDA issued a guidance today entitled Compliance Policy for Cosmetic Product Facility Registration and Cosmetic Product Listing (here) announcing a 6-month period during which the FDA will not take compliance actions against a company for failing to meet the cosmetic listing and facility registration requirements. According to the FDA, the policy is designed to […]
Lachman Consultants’ Vice President Ricki Chase joined Arnold & Porter to discuss the introduction of the Modernization of Cosmetics Regulation Act (MoCRA) including FDA’s authority to formalize good manufacturing practice (cGMP) requirements for the cosmetics industry. This is a landmark change to how cosmetics are filed, manufactured, traced, and reviewed by the Food and Drug […]
